synthetic lethality product pipeline
The latest data show that cancer has become the second leading cause of death in the world causing 10 million people’s death each year globally. There are huge unmet medical needs for cancer treatment. Since foundation in 2009, IMPACT Therapeutics has been dedicated to the discovery and development of novel anti-cancer therapeutics with global rights, building a global leading synthetic lethality product pipeline to address unmet medical needs and make an impact on cancer treatment.
Genomic instability is one of the hallmarks of cancer cells, and the resultant mutations render cancer cells more dependent on alternative pathways for survival and proliferation, so these cancer cells are more vulnerable to targeted perturbations on those alternative pathways – a phenomenon known as synthetic lethality.
Synthetic lethality is an especially attractive and effective approach to targeting some common oncogenes that have been traditionally considered as undruggable. Synthetic lethality also has the potential to overcome the therapeutic resistance caused by new mutations that often occur with the treatment of conventional targeted therapies. Furthermore, therapies addressing synthetic lethality targets can have anti-tumor effects that are complementary to or synergistic with therapeutics employing other mechanisms. Synthetic lethality can be exploited as a drug development approach to selectively target cancer cells with certain mutations, for example, deficiencies in DNA damage response (DDR), and we see this approach usher in a new paradigm for targeted anti-cancer therapy.
Global clinical trial
China clinical trial
To leverage financial, clinical and commercial resources required for the development and eventual sales of IMP4297（senaparib） in China, we have established a joint venture with Junshi Biosciences to develop and commercialize senaparib in China.
We intend to continue exploring partnerships through strategic collaborations including licensing arrangements, co-development and co-commercialization arrangements to maximize the clinical and commercial value of our drug candidates.